

Table 14.8
De Novo Posttransplant Solid Malignancy, 1999 to 2008
Liver Recipients

	Year of Transplant									
	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008
Total # of Post-Tx Malignancies	380	331	323	359	305	323	318	226	123	38
Malignancies by Type										
Squamous/Basal Cell Carcinoma	150	152	134	133	111	115	118	68	34	10
Melanoma	15	5	7	14	10	6	13	7	8	-
Kaposi Sarcoma	5	2	1	3	-	1	-	-	2	-
Central Nervous System	2	1	3	2	2	4	1	5	4	-
Genito-Urinary (1)	32	34	38	28	41	28	28	18	11	4
Gastro-Intestinal (2)	52	35	36	28	36	38	28	29	14	5
Primary Hepatic Tumor	14	16	8	21	16	18	29	11	8	6
Metastatic Hepatic Tumor	6	9	13	17	13	20	21	15	7	2
Larynx/Bronchi/Lung	54	39	44	58	33	54	41	41	16	5
Breast/Thyroid	19	10	15	15	13	9	11	10	2	-
Leukemia	-	2	1	2	5	6	2	-	3	-
Sarcoma (3)	1	1	-	3	3	2	2	-	1	-
Other	22	21	16	31	18	19	23	18	12	6
Unknown	8	4	7	4	4	3	1	4	1	-
Malignancies by Type (%)										
Squamous/Basal Cell Carcinoma	39.5%	45.9%	41.5%	37.0%	36.4%	35.6%	37.1%	30.1%	27.6%	26.3%
Melanoma	3.9%	1.5%	2.2%	3.9%	3.3%	1.9%	4.1%	3.1%	6.5%	-
Kaposi Sarcoma	1.3%	0.6%	0.3%	0.8%	-	0.3%	-	-	1.6%	-
Central Nervous System	0.5%	0.3%	0.9%	0.6%	0.7%	1.2%	0.3%	2.2%	3.3%	-
Genito-Urinary (1)	8.4%	10.3%	11.8%	7.8%	13.4%	8.7%	8.8%	8.0%	8.9%	10.5%
Gastro-Intestinal (2)	13.7%	10.6%	11.1%	7.8%	11.8%	11.8%	8.8%	12.8%	11.4%	13.2%
Primary Hepatic Tumor	3.7%	4.8%	2.5%	5.8%	5.2%	5.6%	9.1%	4.9%	6.5%	15.8%
Metastatic Hepatic Tumor	1.6%	2.7%	4.0%	4.7%	4.3%	6.2%	6.6%	6.6%	5.7%	5.3%
Larynx/Bronchi/Lung	14.2%	11.8%	13.6%	16.2%	10.8%	16.7%	12.9%	18.1%	13.0%	13.2%
Breast/Thyroid	5.0%	3.0%	4.6%	4.2%	4.3%	2.8%	3.5%	4.4%	1.6%	-
Leukemia	-	0.6%	0.3%	0.6%	1.6%	1.9%	0.6%	-	2.4%	-
Sarcoma (3)	0.3%	0.3%	-	0.8%	1.0%	0.6%	0.6%	-	0.8%	-
Other	5.8%	6.3%	5.0%	8.6%	5.9%	5.9%	7.2%	8.0%	9.8%	15.8%
Unknown	2.1%	1.2%	2.2%	1.1%	1.3%	0.9%	0.3%	1.8%	0.8%	-
Total # of Patients	271	254	241	270	228	247	235	173	99	33

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

(-) = None in category.

(1) Genito-Urinary: kidney, bladder, uterine cervix, uterine body, ovarian, vulva, testicular, prostate.

(2) Gastro-Intestinal: tongue, throat, esophagus, stomach, small intestine, colo-rectal, liver and biliary tract, pancreas.

(3) Sarcoma: fibrosarcoma, osteosarcoma, etc.

Recipient malignancy statistics are based on voluntary reporting to the OPTN.